SNSS Sunesis Pharmaceuticals, Inc.

Subscribe to $SNSS

Sunesis Pharmaceuticals, Inc.

Subscribe to $SNSS

$SNSS

Major Pharmaceuticals

Health Care

IPO Year: 2005

Exchange: NASDAQ

Recent Analyst Ratings for Sunesis Pharmaceuticals, Inc.

Date	Price Target	Rating	Analyst

See more ratings

Sunesis Pharmaceuticals, Inc. Press Releases

Fastest customizable press release news feed in the world

View All

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

SAN DIEGO, Feb. 16, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for patent application No. 16/924,082. The allowed application, titled "Methods of Treating Virally Associated Cancers with Histone Deacetylase Inhibitors," describes the use of Viracta's all-oral combination product candidate of nanatinostat, the Company's proprietary investigational drug, and valganciclovir. The allowed claims cover the anticipated dose regimen to be advanced in the planned global registration trial for the trea

2/16/21 8:00:00 AM ET

$SNSS

Major Pharmaceuticals

Health Care

Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

SAN DIEGO, Feb. 11, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced that the Company will participate in the upcoming LifeSci Partners Precision Oncology Day on February 17, 2021 and the 10th Annual SVB Leerink Global Healthcare Conference taking place February 22-26, 2021. The Company will present and participate in one-on-one investor meetings at both conferences. Details on the events can be found below. LifeSci Partners Precision Oncology Day Date: Wednesday, February 17, 2021 Time: 2:30 PM ET Format: Corporate presentation 10th Annual SVB Leerink Globa

2/11/21 4:05:00 PM ET

$SNSS

Major Pharmaceuticals

Health Care

Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

SAN DIEGO, Dec. 7, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (Viracta or the Company), a precision oncology company targeting virus-associated malignancies, today announced recent clinical and regulatory developments regarding its lead program for the treatment of relapsed/refractory (R/R) EBV+ lymphomas. At the 62nd American Society of Hematology (ASH) Annual Meeting, Dr. Pierluigi Porcu of Sidney Kimmel Cancer Center, Thomas Jefferson University, presented updated data from Viracta's ongoing clinical trial evaluating its all-oral combination regimen of nanatinostat and valganciclovir for the treatment of patients with R/R EBV+ lymphoma that had failed one or more prior therapies

12/7/20 8:30:00 AM ET

$SNSS

Major Pharmaceuticals

Health Care

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Merger to create Nasdaq-listed company focused on developing Viracta’s precision oncology pipeline targeting virus-associated malignancies Registration trial for Viracta’s lead program in Epstein-Barr virus (EBV)-positive lymphomas expected to begin in the first half of 2021 Leading institutional investors committed a total of $105 million in private financings with Viracta Combined company expected to have approximately $120 million cash balance following the close of the merger Companies to host conference call today at 8:30 AM Eastern Time SOUTH SAN FRANCISCO and SAN DIEGO, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) and Viracta

11/30/20 7:30:00 AM ET

$SNSS

Major Pharmaceuticals

Health Care

Sunesis Pharmaceuticals, Inc.

Recent Analyst Ratings for Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals, Inc.

Recent Analyst Ratings for Sunesis Pharmaceuticals, Inc.

Sunesis Pharmaceuticals, Inc. Analyst Ratings

Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

Sunesis Pharmaceuticals upgraded by Oppenheimer with a new price target

Sunesis Pharmaceuticals, Inc. Press Releases

Viracta Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering the Use of its Combination Product Candidate for the Treatment of Epstein-Barr Virus-associated Lymphoma

Viracta Therapeutics to Participate in Upcoming Virtual Investor Conferences

Viracta Therapeutics Announces Presentation of Updated Phase 2 Data at ASH 2020 and Productive Outcome of its Recent End of Phase 2 Meeting with the FDA

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Sunesis Pharmaceuticals, Inc. Insider Trading

SEC Form 3 filed by J. Barry Simon

SEC Form 3 filed by Stephen Rubino

SEC Form 3: Partnership Limited Fund 2 Amoon claimed ownership of 7,392,237 units of Common Stock

SEC Form 3: Gur Roshwalb claimed ownership of 7,392,237 units of Common Stock

SEC Form 3: R. Daniel Chevallard claimed ownership of 44,760 units of Common Stock

SEC Form 3 filed by E Thomas Darcy

SEC Form 3 filed by Michael Huang

SEC Form 3 filed by Lafayette Samuel Murphy

SEC Form 3 filed by Roger Pomerantz

SEC Form 3 filed by Lisa Rojkjaer

Sunesis Pharmaceuticals, Inc. SEC Filings

SEC Form 8-K filed

SEC Form 8-K filed

SEC Form 10-K filed

SEC Form 425 filed

SEC Form 8-K filed

SEC Form 425 filed

SEC Form 425 filed

SEC Form EFFECT filed

SEC Form 424B3 filed

SEC Form S-4/A filed

Sunesis Pharmaceuticals, Inc. Financials

Sunesis Pharmaceuticals and Viracta Therapeutics Announce Definitive Merger Agreement

Sunesis Pharmaceuticals, Inc. Large Ownership Changes

SEC Form SC 13D/A filed

SEC Form SC 13G filed

SEC Form SC 13G/A filed

SEC Form SC 13D filed

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed

SEC Form SC 13G/A filed